Pilgrim 10% Vitamin C Face Serum With 5% Niacinamide For Daily Brightness, 10 ml

Achieve glowing, brighter skin in just 5 days (clinically tested) with the specially formulated 10% Vitamin C (3-O-Ethyl Ascorbic Acid) face serum with 5% Niacinamide. This powerful combination works wonders to effectively diminish dark spots and hyperpigmentation, helping you reduce dark spots in as little as 3 days. Perfect for beginners, this serum addresses discolourations and evens out your skin tone, resulting in a smoother, more balanced skin tone. The naturally occurring form of vitamin C is highly unstable, so there is a skincare hero, which is a derivative of Vitamin C, known as 3-O-Ethyl ascorbic acid. The stable form of Vitamin C used in the serum is known for its ability to brighten and enhance skin radiance. It fades pigmentation and provides a powerful antioxidant boost, protecting your skin from environmental damage and promoting a youthful glow.

Complementing this, Niacinamide, a form of Vitamin B3, reduces pigmentation, strengthens the skin barrier, and improves overall skin brightness. It also has soothing properties, making it suitable for all skin types, including sensitive skin. The 10% Vitamin C formula is further enriched with the Australian Kakadu Plum, one of the richest natural sources of Vitamin C. This potent ingredient contains 100 times more Vitamin C than an orange and is packed with antioxidants that improve skin texture and brightness. The combined action of these ingredients targets dark spots and uneven skin tone, giving you a brighter and more radiant complexion. Experience the transformative effects of our serum, which not only brightens and fades pigmentation but also strengthens and protects your skin. With regular use, you'll notice significant improvements in skin texture, tone, and overall health. Say goodbye to dark spots and hello to a luminous, even complexion with our potent, beginner-friendly serum. Enjoy the confidence of glowing, brighter skin in just 5 days. Based on consumer feedback from a clinical study conducted in March 2024 by an independent lab.